Physician profile
Aldijana Sacic
NPI 1740807825
$510,249.64
in general payments reported to CMS, 2019-2025
21 companies · $248K in 2025
The $248K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,842 · 2022: $1,249 · 2023: $70K · 2024: $189K · 2025: $248K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $406K · Travel and Lodging: $60K · Consulting Fee: $28K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $405,664.00 |
| Travel and Lodging | $59,746.15 |
| Consulting Fee | $27,751.00 |
| Food and Beverage | $13,997.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $314,421.62 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $155,690.25 | 2022-2025 | Invega Sustenna, Invega Trinza, Invega |
| Otsuka America Pharmaceutical, INC. | $37,026.38 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $860.92 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $672.42 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Acadia Pharmaceuticals INC | $335.13 | 2021-2023 | Nuplazid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $322.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $266.24 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $116.73 | 2021 | |
| Neurelis, INC. | $93.72 | 2023-2024 | Valtoco |
| Indivior INC. | $92.37 | 2021-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $71.86 | 2023-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $64.90 | 2021 | |
| Vanda Pharmaceuticals INC. | $55.66 | 2021 | |
| Ucb, INC. | $53.44 | 2023 | Fintepla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.88 | 2023-2024 | Auvelity |
| Abbvie INC. | $18.35 | 2022 | |
| Lundbeck LLC | $16.36 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $16.00 | 2021 | |
| Almatica Pharma LLC | $15.99 | 2023 | Loreev Xr |
| Bausch Health US, LLC | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aldijana Sacic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.